Results 231 to 240 of about 42,521 (302)

Updates on Mediterranean diet and health status: active ingredients and pharmacological mechanisms

British Journal of Pharmacology, EarlyView.
The Mediterranean diet (MedDiet) is among the most extensively studied dietary patterns and has been consistently associated with reduced risk of all‐cause mortality, cardiovascular disease, metabolic disorders, cognitive decline and several types of cancers.
Lukas Schwingshackl, Jakub Morze, Sabina Wallerer, Georg Hoffmann   +3 more
wiley   +1 more source

Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation. [PDF]

Europace
Ciconte G, Salerno R, Fuga A, Vuturo A, Boccellino A, Negro G, Rondine R, Ballarotto M, Ciaccio C, Izzo A, Morciano DA, Garbelli A, Giannelli L, Maiolo V, Calovic Z, Anastasia L, Pappone C.   +16 more
europepmc   +1 more source

Dual pharmacological targeting of coactivator‐associated arginine methyltransferase 1 (CARM1) and salt inducible kinase (SIK) drives ketogenesis in both hepatocytes and mice

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Ketone bodies are liver‐derived circulating energy metabolites that positively impact most hallmarks of ageing. Ketone bodies increase during calorie restriction and fasting, two of the more widely perceived methods to increase health span.
Tábata Bergonci, Troels Kjær Rosenbæk, Samuel J. Windross, Ulrik B. Keiding, Estéfano Pinilla, Katrine P. Stuckert, Jakob Hansen, Camilla B. Nielsen, Jemila Peter Gomes, Lucy R. Davies, Johan Palmfeldt, Volker Loeschcke, Charlotte U. Andersen, Ulf Simonsen, Thomas B. Poulsen, Mogens Johannsen   +15 more
wiley   +1 more source

Research progress in precision medicine for type 2 diabetes based on the GLP-1. [PDF]

Front Endocrinol (Lausanne)
Wang S, Yuan C, Wang H, Ye X, Ruan S, Yi L, Yang W, Wang Z, Wang N, Li J, Feng X, Li Y, Tian Y, Wang Q.   +13 more
europepmc   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population. [PDF]

J Manag Care Spec Pharm
Meyer KB, McVeigh M, Chiara AN, Boss KC, Pomfret TC, Semmel K, Bacon R, Nicolas D, Clements K, Alper CJ, Lenz K.   +10 more
europepmc   +1 more source

Dynamics of Apolipoprotein J Levels and Metabolic Parameters Following Bariatric Surgery

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Bariatric surgery has emerged as a potent intervention for ameliorating insulin resistance and its associated comorbidities in obese patients. Apolipoprotein J (ApoJ) and adiponectin are closely associated with insulin resistance and sensitivity, respectively.
Kellen Cristina da Cruz Rodrigues, Minjin Lee, Yejee Lim, Jennie Young, Brendon Chung, Susan Phillips, Theodore P. Ciaraldi, Young‐Bum Kim   +7 more
wiley   +1 more source

Self-Assembly of a Therapeutic Peptide Surfactant: A Small-Angle X-ray Scattering Study. [PDF]

Langmuir
Brunzell E, Sigfridsson K, Bergström LM.   +2 more
europepmc   +1 more source

Is There a Causal Link Between GLP‐1 Receptor Agonists and Non‐Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for managing Type 2 diabetes and obesity, with well‐documented and significant cardiometabolic benefits. Recent observational reports and pharmacovigilance data have raised concerns about a possible association between GLP‐1RAs‐particularly semaglutide‐ and non‐arteritic ...
Helen V. Danesh‐Meyer, Joseph F. Rizzo III   +1 more
wiley   +1 more source

Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet, Iain K. Robertson, Sharon P. Luccisano, Michelle L. Kilpatrick   +3 more
wiley   +1 more source